Dyne Therapeutics Inc (NAS:DYN)
$ 26 0.05 (0.19%) Market Cap: 2.27 Bil Enterprise Value: 1.85 Bil PE Ratio: 0 PB Ratio: 4.69 GF Score: 37/100

Dyne Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 10:15PM GMT
Release Date Price: $18.77 (+4.10%)
Tessa Romero J.P. Morgan;Analyst

Welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Tessa Romero and one of the biotechnology analysts here at JPMorgan. Our next presenting company is Dyan therapeutics and speaking, on behalf of the Company, we have CEO, Josh Brumm. Josh, over to you.

Josh Brumm Dyne Therapeutics Inc.;CEO

Thanks, Tom, and good afternoon, everybody. It's great to be here. Thank you to Morgan Stanley for the invite and thank you for all attending a pretty exciting story for us to tell here kicking off the year.I'll start with forward-looking statements we may make today. Please see our SEC filings for more information on those matters.

Ultimately, what I want to do is just give a very brief overview introduction and Willdan is going to come up and as you may know, we put out some data, so proof-of-concept data clinically in both Tier one and in our DMD program last week. And once we have enough representation of that of that data. So we're looking forward to it. I wanted to start by just

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot